<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795676</url>
  </required_header>
  <id_info>
    <org_study_id>PB-102-F20</org_study_id>
    <nct_id>NCT02795676</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function</brief_title>
  <acronym>BALANCE</acronym>
  <official_title>A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, active control study of PRX-102 (pegunigalsidase alfa) in
      Fabry disease patients with impaired renal function. Patients treated for approximately 1
      year with agalsidase beta and on a stable dose for at least 6 months will be screened and
      then randomized to continue treatment with 1mg/kg agalsidase beta or to treatment with 1
      mg/kg of PRX-102. The identity of the enzyme will be blinded to the patient and the
      investigator. Patients will receive intravenous infusions every two weeks. Patients will be
      randomized in a 2:1 ratio of PRX-102 to agalsidase beta. Randomization will be stratified by
      urinary protein to creatinine ratio (UPCR) of &lt; or ≥ 1 g/g by spot urine sample. No more than
      50% of the patients will be female.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eGFR Slope</measure>
    <time_frame>Every month for 2 years</time_frame>
    <description>eGFR Slope</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Mass Index (g/m2) by MRI</measure>
    <time_frame>Every 12 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Lyso-Gb3</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Gb3</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Lyso-GB3</measure>
    <time_frame>Every 6 weeks for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein/creatinine ratio</measure>
    <time_frame>Every 4 months for 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of pain medication use</measure>
    <time_frame>Every 2 weeks for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise tolerance (Stress Test)</measure>
    <time_frame>Every year for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Brief Pain Inventory (BPI)</measure>
    <time_frame>Every 6 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mainz Severity Score Index (MSSI)</measure>
    <time_frame>Every 6 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life EQ-5D-5L</measure>
    <time_frame>Every 6 months for 2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>PRX-102 pharmacokinetics</measure>
    <time_frame>Every 6 months for 2 years</time_frame>
    <description>PRX-102 pharmacokinetics parameters</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-drug IgG antibodies</measure>
    <time_frame>Every 2 weeks for 1 month, then every month for the first 6 months and every 3 month until the end of the study</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>PRX-102 (pegunigalsidase alfa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 infusion every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>agalsidase beta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>agalsidase beta infusion every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRX-102 (pegunigalsidase alfa)</intervention_name>
    <description>PRX-102 1 mg/kg every 2 weeks</description>
    <arm_group_label>PRX-102 (pegunigalsidase alfa)</arm_group_label>
    <other_name>pegunigalsidase alfa</other_name>
    <other_name>Recombinant human alpha galactosidase-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>agalsidase beta</intervention_name>
    <description>agalsidase beta 1 mg/kg every 2 weeks</description>
    <arm_group_label>agalsidase beta</arm_group_label>
    <other_name>Fabrazyme</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic adult Fabry disease patients, age 18-60 years

               1. Males: Plasma and/or leucocyte alpha galactosidase activity (by activity assay)
                  less than 30% mean normal levels and one or more of the characteristic features
                  of Fabry disease

                  i. neuropathic pain

                  ii. cornea verticillata

                  iii. clustered angiokeratoma

               2. Females:

                  a. historical genetic test results consistent with Fabry pathogenic mutation and
                  one or more of the described characteristic features of Fabry disease:

                  i. neuropathic pain

                  ii. cornea verticillata

                  iii. clustered angiokeratoma

                  b. or in the case of novel mutations a first degree male family member with Fabry
                  disease with the same mutation, and one or more of the characteristic features of
                  Fabry disease

                  i. neuropathic pain

                  ii. cornea verticillata

                  iii. clustered angiokeratoma

          -  Screening eGFR by CKD-EPI equation 40 to 120 mL/min/1.73 m²

          -  Linear negative slope of eGFR based on at least 3 serum creatinine values over
             approximately 1 year (range of 9 to 18 months, including the value obtained at the
             screening visit) of ≥ 2 mL/min/1.73 m²/year

          -  Treatment with a dose of 1 mg/kg agalsidase beta per infusion every 2 weeks for at
             least one year and at least 80% of 13 (10.4) mg/kg total dose over the last 6 months.

          -  Female patients and male patients whose co-partners are of child-bearing potential
             agree to use a medically accepted method of contraception, not including the rhythm
             method.

        Exclusion Criteria:

          -  History of anaphylaxis or Type 1 hypersensitivity reaction to agalsidase beta

          -  Known non-pathogenic Fabry mutations

          -  History of renal dialysis or transplantation

          -  History of acute kidney injury in the 12 months prior to screening, including specific
             kidney diseases (e.g., acute interstitial nephritis, acute glomerular and vasculitic
             renal diseases); non-specific conditions (e.g, ischemia, toxic injury); as well as
             extrarenal pathology (e.g., prerenal azotemia, and acute postrenal obstructive
             nephropathy)

          -  Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)
             therapy initiated or dose changed in the 4 weeks prior to screening

          -  Patient with a screening eGFR value between 91-120 mL/min/1.73 m², having an
             historical eGFR value higher than 120 mL/min/1.73 m² (during 9 to 18 months before
             screening)

          -  Urine protein to creatinine ratio (UPCR) &gt; 0.5 g/g and not treated with an ACE
             inhibitor or ARB

          -  Cardiovascular event (myocardial infarction, unstable angina) in the 6 month period
             before randomization

          -  Congestive heart failure NYHA Class IV

          -  Cerebrovascular event (stroke, transient ischemic attack) in the 6 month period before
             randomization

          -  Known history of hypersensitivity to Gadolinium contrast agent that is not managed by
             the use of pre-medication

          -  Female subjects who are pregnant, planning to become pregnant during the study, or are
             breastfeeding

          -  Presence of any medical, emotional, behavioral or psychological condition that, in the
             judgment of the Investigator and/or Medical Director, would interfere with the
             patient's compliance with the requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul Chertkoff, MD</last_name>
    <role>Study Director</role>
    <affiliation>Protalix Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>30020-8341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida, Department of Pediatrics/Genetics &amp; Metabolism</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hosptials and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infusion Associates</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regents of the University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Metabolic Disease, Baylor Healthcare</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eccles Primary Children's Outpatient Services Building</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O+O Alpan LLC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Nefrologia Pergamino SRL</name>
      <address>
        <city>Pergamino</city>
        <state>Buenos Aires</state>
        <zip>2700</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Prague</city>
        <state>Czech Republic</state>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré</name>
      <address>
        <city>Paris</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi (SOD Nefrologia)</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria &quot;Federico II&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli, L.go A. Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital Klinisk Forskningspost</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Clinical Research Private Institute</name>
      <address>
        <city>Asuncion</city>
        <zip>1141</zip>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Slovenj Gradec</name>
      <address>
        <city>Slovenj Gradec</city>
        <zip>2380</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Dia Quiron Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Innere Medizin UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department and Laboratory of Pediatric Metabolic Disorders</name>
      <address>
        <city>Ankara</city>
        <zip>6500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege Universty Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Metabolism and Systems Research</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Paraguay</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 2, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glomerular filtration rate</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>PRX-102</keyword>
  <keyword>pegunigalsidase alfa</keyword>
  <keyword>Fabry Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

